Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder

We assessed the efficacy and tolerability of the augmentation of antidepressants (ATDs) with atypical antipsychotics (AAPs) to treat patients with major depressive disorder. A retrograde study to identify relevant patient data included databases of PubMed, EMBASE, Cochrane Central Register of Contro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Brazilian journal of medical and biological research 2014-07, Vol.47 (7), p.605-616
Hauptverfasser:	Wen, X J, Wang, L M, Liu, Z L, Huang, A, Liu, Y Y, Hu, J Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjunctive therapy Adolescent Adult Aged Antidepressants Antidepressive Agents - administration & dosage Antidepressive Agents - adverse effects Antipsychotic agents Antipsychotic Agents - administration & dosage Antipsychotic Agents - adverse effects Aripiprazole Atypical antipsychotics Benzodiazepines - administration & dosage Benzodiazepines - adverse effects BIOLOGY Chemotherapy, Adjuvant Clinical Investigation Depressive Disorder, Major - drug therapy Dibenzothiazepines - administration & dosage Dibenzothiazepines - adverse effects Dosage and administration Double-Blind Method Drug Synergism Drug therapy Humans Major depressive disorder MEDICINE, RESEARCH & EXPERIMENTAL Meta-analysis Middle Aged Olanzapine Piperazines - administration & dosage Piperazines - adverse effects Quetiapine Fumarate Quinolones - administration & dosage Quinolones - adverse effects Randomized Controlled Trials as Topic Remission Induction Risperidone - administration & dosage Risperidone - adverse effects Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We assessed the efficacy and tolerability of the augmentation of antidepressants (ATDs) with atypical antipsychotics (AAPs) to treat patients with major depressive disorder. A retrograde study to identify relevant patient data included databases of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Database of Abstracts of Reviews of Effects. Data from 17 trials, involving 3807 participants, were identified. The remission rate (RR) and overall response rate (ORR) of adjunctive treatment with AAPs were significantly higher than placebo treatment: RR=1.90 (95%CI=1.61-2.23, z=7.74, P
ISSN:	0100-879X 1414-431X 1414-431X
DOI:	10.1590/1414-431X20143672